Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EXFORGE vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Exforge is a combination of amlodipine, a dihydropyridine calcium channel blocker, and valsartan, an angiotensin II receptor blocker. Amlodipine inhibits calcium influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation. Valsartan selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation and reduced aldosterone secretion.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Treatment of hypertension,Management of hypertension in patients who are not adequately controlled on monotherapy,Initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
One tablet orally once daily. Initial dose: 5/160 mg or 5/320 mg. Titrate based on blood pressure response. Maximum dose: 10/320 mg once daily.
250 mg orally twice daily
Amlodipine: terminal elimination half-life is 30-50 hours (mean ~35 h), supporting once-daily dosing. Valsartan: terminal half-life is approximately 6 hours, with the combination product dosed once daily due to amlodipine's long half-life.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Amlodipine is extensively metabolized in the liver via CYP3A4 to inactive metabolites. Valsartan is primarily eliminated unchanged in feces and urine; only about 20% is metabolized by CYP2C9.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Valsartan is primarily eliminated via biliary excretion (83%) in feces as unchanged drug; renal excretion accounts for 13% (mostly unchanged). Amlodipine is extensively metabolized in the liver, with 60% of metabolites excreted renally and 20-25% in feces as unchanged drug.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Amlodipine: ~93% bound to plasma proteins. Valsartan: 94-97% bound to serum albumin.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Amlodipine: Vd is approximately 21 L/kg, indicating extensive extravascular distribution. Valsartan: Vd is about 17 L, not weight-adjusted, indicating distribution mainly in plasma and extracellular fluid.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral bioavailability: Amlodipine 64-90%; Valsartan about 25% (with wide interindividual variability). Food decreases valsartan absorption by about 40-50%, but does not affect amlodipine absorption.
70-90% (oral); 100% (IV).
For GFR 30-60 m L/min: no adjustment. For GFR <30 m L/min: not recommended due to lack of data. Contraindicated if GFR <30 m L/min due to hydrochlorothiazide component.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: no adjustment. Child-Pugh B: not recommended. Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Safety and efficacy not established in pediatric patients below 18 years.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
No dose adjustment required based on age alone. Initiate at lower end of dosing range (5/160 mg) due to potential for increased sensitivity to hypotension. Monitor renal function closely.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
Exforge contains valsartan, which can cause fetal harm when used during pregnancy. If pregnancy is detected, discontinue Exforge as soon as possible.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Fetal toxicity,Hypotension in salt- or volume-depleted patients,Impaired renal function,Hyperkalemia,Angioedema,Hepatic impairment,Severe obstructive coronary artery disease
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Pregnancy,Hypersensitivity to amlodipine, valsartan, or any component of the formulation,Concomitant use with aliskiren in patients with diabetes
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid grapefruit juice (increases amlodipine AUC by 56%). High-potassium foods (bananas, oranges, spinach) may increase hyperkalemia risk; no specific restriction but monitor intake if renal impairment.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
Pregnancy Category D. First trimester: Potential fetal toxicity; risk of malformations not significantly increased based on limited data. Second and third trimesters: Oligohydramnios, fetal renal dysfunction, skull ossification defects, hypotension, hyperkalemia, and anuria due to angiotensin II receptor antagonist (valsartan) component. Amlodipine may cause fetal hypoxia due to uterine hypoperfusion.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
No data on Exforge in breast milk. Valsartan is excreted in rat milk; amlodipine is excreted in human milk (M/P ratio unknown). Due to potential adverse effects in nursing infants (hypotension, renal effects), avoid breastfeeding. If used, monitor infant for hypotension and renal function.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Exforge is contraindicated in pregnancy. No dose adjustment can mitigate fetal risk. Alternative antihypertensive therapy is recommended. If inadvertently used, discontinue immediately and switch to a safe alternative.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
EXFORGE (amlodipine/valsartan) combines a dihydropyridine calcium channel blocker with an angiotensin II receptor blocker. It is contraindicated in pregnancy (fetal nephrotoxicity, oligohydramnios). Monitor serum potassium and renal function, especially in older adults, volume-depleted patients, or those with renal impairment. Avoid use with aliskiren in patients with diabetes or GFR <60 m L/min. Peripheral edema is less than amlodipine alone due to vasodilation balance.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Do not take if pregnant or planning pregnancy; use effective contraception.,Avoid grapefruit juice as it increases amlodipine levels and risk of hypotension.,Take the same time each day; do not skip doses or double up.,May cause dizziness or lightheadedness; avoid driving until you know how it affects you.,Report swelling in hands/feet, irregular heartbeat, or signs of angioedema (swelling of face/lips).
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EXFORGE vs ALDOCLOR-250, answered by our medical review team.
EXFORGE is a Antihypertensive that works by Exforge is a combination of amlodipine, a dihydropyridine calcium channel blocker, and valsartan, an angiotensin II receptor blocker. Amlodipine inhibits calcium influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation. Valsartan selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation and reduced aldosterone secretion.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EXFORGE and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EXFORGE is: One tablet orally once daily. Initial dose: 5/160 mg or 5/320 mg. Titrate based on blood pressure response. Maximum dose: 10/320 mg once daily.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EXFORGE and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EXFORGE is classified as Category C. Pregnancy Category D. First trimester: Potential fetal toxicity; risk of malformations not significantly increased based on limited data. Second and third trimesters: Oligohydramni. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.